Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: A single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 10, 2015, Pages 883-889

  Chae, Dong Woo ^a,b   Son, Mijeong ^a,b   Kim, Yukyung ^a,b   Son, Hankil ^a,b   Jang, Seong Bok ^c   Seo, Jeong Min ^c   Nam, Su Youn ^c   Park, Kyungsoo ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yuhan Corporation   (South Korea)

Author keywords

Bioequivalence; FDC; Pharmacokinetics; Rosuvastatin; Telmisartan

Indexed keywords

ROSUVASTATIN; ROSUVASTATIN PLUS TELMISARTAN; TELMISARTAN; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DRUG COMBINATION;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; HEADACHE; HUMAN; INTERVIEW; KOREAN (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHYSICAL EXAMINATION; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; DRUG COMBINATION;

ADULT; BENZIMIDAZOLES; BENZOATES; CROSS-OVER STUDIES; DRUG COMBINATIONS; HUMANS; MALE; ROSUVASTATIN CALCIUM;

EID: 84946914796     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202412     Document Type: Article

References (15)

1. Lithell H. Hypertension and hyperlipidemia. A review. Am J Hypertens. 1993; 6 (11 Pt 2): 303S-308S. CrossRef PubMed
2. Ames RP. Hyperlipidemia in hypertension: causes and prevention. Am Heart J. 1991; 122 (4 Pt 2): 1219-1224. CrossRef PubMed
3. Wolfgang W. A Review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist. Cardiovasc Drug Rev. 2000; 18: 127-154.
4. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs. 2004; 4: 117-138. CrossRef PubMed
5. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003; 1: 495-505. CrossRef PubMed
6. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002; 42: 963-970. CrossRef PubMed
7. Kim-Mitsuyama S. Combination therapy of angiotensin receptor blocker with statin or thiazolidinediones as promising therapeutic strategy for metabolic syndrome and atherosclerosis. Hypertens Res. 2009; 32: 639-640. CrossRef PubMed
8. World Health Organization. WHO Drug Information. WHO Drug Information 2003;17.
9. Wan X, Ma P, Zhang X. A promising choice in hypertension treatment: Fixed-dose combinations. Asian Journal of Pharmaceutical Sciences. 2014; 9: 1-7. CrossRef
10. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. 2008.
11. Korea Food and Drug Administration. Korea Good Clinical Practice Guidelines [in Korean]. http://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do. Accessed Feb 05, 2015.
12. Korea Ministry of Food and Drug Safety. Guideline on Food-Effect Bioavailability and Fed Bioequivalence Studies [in Korean]. http://www.mfds.go.kr. Accessed Feb 05, 2015.
13. James D. Terish, S. Suresh Kumar, Ramesh N and Sasi jith SL. Estimation of Telmisartan in Human Plasma by Reversed Phase Liquid Chromatography Coupled with Tandem Mass Spectrometry - A Bioequivalence Study Application. Der Pharmacia Lettre. 2011; 3: 289-298.
14. Lan K, Jiang X, Li Y, Wang L, Zhou J, Jiang Q, Ye L. Quantitative determination of rosuvastatin in human plasma by ion pair liquid-liquid extraction using liquid chromatography with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2007; 44: 540-546. CrossRef PubMed
15. Crestor (rosuvastatin) tablets. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/21366slr005lbl.pdf. Accessed July 12, 2015.